PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25400145-5	2014	Calcein AM, the cell-permeable derivative of calcein, shows significant antitumour activity in a wide spectrum of cultured cancer cells harbouring high TopBP1 levels.	calcein AM	0-10	DNA topoisomerase II binding protein 1	Homo sapiens	152-158	
28628491-5	2017	Furthermore, we found that TopBP1, which we previously showed was involved in doxorubicin resistance through upregulation of aberrant p53, was involved in calcein-AM-mediated increased doxorubicin sensitivity.	calcein AM	155-165	DNA topoisomerase II binding protein 1	Homo sapiens	27-33	
28628491-7	2017	Calcein-AM repressed the expression of TopBP1, which resulted in reduced expression of aberrant p53 and disrupted the antiapoptotic activity mediated by the TopBP1/mutp53 pathway in NSCLC.	calcein AM	0-10	DNA topoisomerase II binding protein 1	Homo sapiens	39-45	
28628491-7	2017	Calcein-AM repressed the expression of TopBP1, which resulted in reduced expression of aberrant p53 and disrupted the antiapoptotic activity mediated by the TopBP1/mutp53 pathway in NSCLC.	calcein AM	0-10	DNA topoisomerase II binding protein 1	Homo sapiens	157-163	
28628491-8	2017	Together, our findings show that calcein-AM, the cell-permeable derivative of calcein, exerts significant antitumor effects in NSCLC, and can enhance the antitumor effect of doxorubicin by regulating the TopBP1/mutp53 pathway.	calcein AM	33-43	DNA topoisomerase II binding protein 1	Homo sapiens	204-210